We have created a highly focused and productive research organization that has progressed a number of internal compounds into the clinic since our founding in 2002. Anacor has a Pipeline, with an expanding clinical development portfolio focused on developing clinical compounds in our two core therapeutic areas of dermatology and anti-infectives. In addition, Anacor is developing systemic antibacterial therapeutics under a research and development agreement with GlaxoSmithKline.